Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MedWatch

This article was originally published in The Tan Sheet

Executive Summary

FDA posts message for health professionals Aug. 25 asking them to report any serious adverse events that occur with use of dietary supplements containing GBL, GHB or BD to the MedWatch database. FDA has issued warnings to consumers of the dangers of gamma butyrolactone, gamma hydroxybutyric acid and 1,4 butanediol through "Talk Papers" and flyers sent to health care professional organizations and publications, school boards and health club associations (1"The Tan Sheet" June 28, p. 5). The agency has asked manufacturers to cease marketing dietary supplements containing the ingredients, for which it has safety concerns

You may also be interested in...



FDA Flyers Warn Consumers Of Dangerous BD, GBL, GHB Supplements

FDA sent flyers to health care professional organizations and publications, school boards and health club associations June 15 warning of the danger from dietary supplements containing 1,4 butanediol (BD), gamma butyrolactone (GBL) and gamma hydroxybutyric acid (GHB). The agency asked the organizations to disseminate the flyers in prominent places and publish the information in publications, magazines or association/company newsletters.

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Topics

UsernamePublicRestriction

Register

PS090252

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel